Drug Target (Or Biomarker) Identification and characterization for DNAAF2 (CILD10)

Target Name: DNAAF2

NCBI ID: G55172

DNAAF2

Drug Target (Or Biomarker) Identification and characterization for DNAAF2 (CILD10)

Background

DNA damage-inducible acute-illumination (DNAAF)2 is a non-coding RNA molecule that has been identified as a potential drug target in various diseases, including cancer. Its unique mechanism of gene regulation, as well as its involvement in cellular processes such as DNA replication, has made it an attractive target for researchers to investigate.

DNAAF2 has been shown to play a crucial role in the regulation of cell proliferation and apoptosis, which are important processes that are critical for the development and progression of many diseases. It has been shown to regulate the expression of genes involved in cell cycle progression, DNA replication, and apoptosis, among others.

Recent studies have also shown that DNAAF2 is involved in the regulation of cell adhesion, which is a process that is critical for the development of various diseases, including cancer. It has been shown to play a role in the regulation of tight junction formation, which is a process that helps to maintain the integrity of tissues and is critical for the development of cancer.

DNAAF2 has also been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed. This process is critical for the development of many diseases, including cancer. It has been shown to play a role in the regulation of vascular endothelial growth factor (VEGF), which is a protein that plays a critical role in the development of blood vessels.

DNAAF2 has also been shown to be involved in the regulation of inflammation, which is a process that is critical for the development and progression of many diseases. It has been shown to play a role in the regulation of cytokine production and the regulation of immune cell function.

In conclusion, DNAAF2 is a promising drug target due to its unique mechanism of gene regulation and its involvement in various cellular processes that are critical for the development and progression of many diseases. Further research is needed to fully understand the role of DNAAF2 in disease progression and to identify potential drugs that can target it.

Targeting DNAAF2

One approach to targeting DNAAF2 is to use small molecules, such as drugs, to inhibit its activity. This can be done by binding to specific regions of the molecule, such as its protein domain or its mRNA, and preventing it from carrying out its intended function.

Another approach to targeting DNAAF2 is to use antibodies, such as monoclonal antibodies (mAbs), to recognize and target specific regions of the molecule. This can be done by using antibodies that are designed to recognize specific epitopes (one-on-one binding) on DNAAF2, and then using these antibodies to block its activity.

Another approach to targeting DNAAF2 is to use genetic modifiers, such as RNA interference (RNAi) technology, to knockdown (reduce the amount of) DNAAF2 in the cell. This can be done by using RNAi-mediated knockdown, where small interfering RNA (siRNA) molecules are designed to target specific regions of the molecule and are introduced into the cell to reduce its levels.

Another approach to targeting DNAAF2 is to use protein-based inhibitors, such as small interfering RNA (siRNA) or protein inhibitors, to prevent its activity. This can be done by using siRNA or protein inhibitors to bind to specific regions of the molecule and prevent it from carrying out its intended function.

Overall, there are various approaches that can be used to target DNAAF2, and further research is needed to determine the most effective and efficient methods.

Protein Name: Dynein Axonemal Assembly Factor 2

Functions: Required for cytoplasmic pre-assembly of axonemal dyneins, thereby playing a central role in motility in cilia and flagella. Involved in pre-assembly of dynein arm complexes in the cytoplasm before intraflagellar transport loads them for the ciliary compartment

The "DNAAF2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNAAF2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets